Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.
暂无分享,去创建一个
Hong Wu | Paul Cairns | Andrew K Godwin | Tianyu Li | Hua Li | Rugang Zhang | Q. Cai | M. Birrer | A. Godwin | Hua Li | Tianyu Li | X. Hua | Rugang Zhang | Hong Wu | P. Cairns | Michael J Birrer | Xiang Hua | B. Bitler | Qi Cai | Benjamin G Bitler | Jasmine P Nicodemus | J. Nicodemus
[1] Hosoon Choi,et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent β-catenin degradation , 2003, The Journal of cell biology.
[2] C. Oshima,et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. , 2009, Oncology reports.
[3] Q. Tao,et al. WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma , 2010, Cancer biology & therapy.
[4] Hongli Yu,et al. Wnt5a as a Predictor in Poor Clinical Outcome of Patients and a Mediator in Chemoresistance of Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.
[5] A. Bradley,et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. , 2003, Cancer cell.
[6] Kathleen R. Cho,et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.
[7] Q. Cai,et al. Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells , 2010, Molecular Cancer Research.
[8] R. Moon. Faculty Opinions recommendation of Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. , 2006 .
[9] R. Nusse,et al. Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.
[10] Frédérick A. Mallette,et al. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence , 2004, Oncogene.
[11] C Roskelley,et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[12] Goberdhan P Dimri,et al. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. , 2007, Methods in molecular biology.
[13] W F Bodmer,et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[15] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[16] Rugang Zhang,et al. Molecular Dissection of Formation of Senescence-Associated Heterochromatin Foci , 2007, Molecular and Cellular Biology.
[17] Rosa Bernardi,et al. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies , 2007, Nature Reviews Molecular Cell Biology.
[18] M. Collado. Exploring a 'pro-senescence' approach for prostate cancer therapy by targeting PTEN. , 2010, Future oncology.
[19] P. Adams. Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. , 2009, Molecular cell.
[20] Pier Paolo Pandolfi,et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.
[21] Ajamete Kaykas,et al. WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.
[22] D. Connolly,et al. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non‐Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In Situ: Applications in Evaluating Novel Therapeutic Agents , 2009, Current protocols in pharmacology.
[23] Pier Paolo Pandolfi,et al. The Role of PML in Tumor Suppression , 2002, Cell.
[24] T. Andersson,et al. The Wnt-5a–Derived Hexapeptide Foxy-5 Inhibits Breast Cancer Metastasis In vivo by Targeting Cell Motility , 2008, Clinical Cancer Research.
[25] H. Westphal,et al. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. , 1992, Cancer research.
[26] A. Silver,et al. The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.
[27] D. Porteous,et al. Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. , 1999, Genome research.
[28] R. Uzzo,et al. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. , 2006, Cancer research.
[29] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[30] D. Peeper,et al. The essence of senescence. , 2010, Genes & development.
[31] E B Cox,et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.
[32] S. Lowe,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2011, Nature.
[33] M. Birrer,et al. Genomic analysis of epithelial ovarian cancer , 2008, Cell Research.
[34] D. Peeper. PICS-ure this: prosenescence therapy? , 2010, Cancer cell.
[35] M. Katoh,et al. WNT Signaling Pathway and Stem Cell Signaling Network , 2007, Clinical Cancer Research.
[36] M. Lipinski,et al. Definition of pRB- and p53-Dependent and -Independent Steps in HIRA/ASF1a-Mediated Formation of Senescence-Associated Heterochromatin Foci , 2007, Molecular and Cellular Biology.
[37] Randall T Moon,et al. WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.
[38] W. Wong,et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. , 2009, Cancer cell.
[39] R. Ozols,et al. Focus on epithelial ovarian cancer. , 2004, Cancer cell.
[40] J. Herman,et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.
[41] Robert A. Weinberg,et al. Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.
[42] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[43] Rugang Zhang,et al. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. , 2007, Molecular cell.
[44] K. Brennand,et al. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics , 2008, Proceedings of the National Academy of Sciences.
[45] Adrian A Canutescu,et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. , 2005, Developmental cell.
[46] T. Pukrop,et al. The complex pathways of Wnt 5a in cancer progression , 2008, Journal of Molecular Medicine.
[47] Y. Minami,et al. Cell/tissue-tropic Functions of Wnt5a Signaling in Normal and Cancer Cells , 2022 .
[48] David F Jarrard,et al. Therapy-induced senescence in cancer. , 2010, Journal of the National Cancer Institute.
[49] S. Lowe,et al. PML is induced by oncogenic ras and promotes premature senescence. , 2000, Genes & development.
[50] J. Clohessy,et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. , 2010, The Journal of clinical investigation.
[51] Ie-Ming Shih,et al. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.
[52] Thomas Earnest,et al. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. , 2002, Developmental cell.